Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
Keywords:Clinical trial, Hdm2, Inhibitor, Mdm2, Nvp-cgm097, Nvp-hdm201, P53, Protein–protein interaction, Ppi
AbstractAs a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.
How to Cite
P. Holzer, Chimia 2017, 71, 716, DOI: 10.2533/chimia.2017.716.
Copyright (c) 2017 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.